CSBTF (Kuros Biosciences) Moat Score: 3/10 (As of Jun. 27, 2026)


CSBTF Kuros Biosciences Ltd CSBTF
71 GF Score
Price $22.72
GF Value $54.72
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Kuros Biosciences Moat Score?

Kuros Biosciences CSBTF 71 Moat Score is 3 as of Jun. 27, 2026. GuruFocus rates CSBTF with a GF Score™ of 71/100 and a GF Value™ of $54.72 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 846 Medical Devices & Instruments companies, Kuros Biosciences ranks better than 75.77% on this metric.

Kuros Biosciences has the Moat Score of 3, which implies that the company might have No Moat - Very weak/transient advantages.

Kuros Biosciences has No Moat: Kuros Biosciences Ltd operates in the biotech sector with limited market presence and lacks significant intellectual property or regulatory barriers. The company does not exhibit strong brand loyalty or cost advantages, resulting in a weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Kuros Biosciences might have No Moat - Very weak/transient advantages.

Kuros Biosciences  (OTCPK:CSBTF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Kuros Biosciences Moat Score Related Terms

CSBTF vs ABT, SYK, MDT: Moat Score Comparison

For the Medical Devices subindustry, Kuros Biosciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kuros Biosciences Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Kuros Biosciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Kuros Biosciences's Moat Score falls into.


CSBTF
71GF Score
Kuros Biosciences Ltd CSBTF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 3 mean?
Kuros Biosciences (CSBTF) has a Moat Score of 3 as of Jun. 27, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Kuros Biosciences ranks #205 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 24.2%.
Is Kuros Biosciences' Moat Score too high?
Kuros Biosciences' current Moat Score is 3. Based on the distribution chart, Kuros Biosciences ranks #205 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Kuros Biosciences has a GF Score™ of 71/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Kuros Biosciences' Moat Score compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Kuros Biosciences ranks #205 out of 846 companies for Moat Score. This places Kuros Biosciences in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Kuros Biosciences's current Moat Score is 3. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kuros Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Kuros Biosciences (CSBTF) is currently considered Significantly Undervalued. The stock's GF Value™ is $54.72, compared to a current price of $22.72 — trading 58.5% below its estimated fair value. The current Moat Score is 3. Kuros Biosciences' overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Kuros Biosciences (CSBTF), the current Moat Score is 3 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kuros Biosciences (CSBTF) Overvalued in 2026?

Based on GuruFocus' analysis, Kuros Biosciences stock appears to be undervalued. The current stock price of $22.72 is trading 58.5% below its estimated GF Value™ of $54.72. GuruFocus considers Kuros Biosciences to be Significantly Undervalued.

Key valuation signals for CSBTF:

  • Moat Score: 3
  • GF Value™: $54.72 vs. price of $22.72 (58.5% below fair value)
  • GF Score™: 71/100 with 2 warning signs

No single metric tells the full story. See the CSBTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kuros Biosciences Business Description

Address Wagistrasse 25, Schlieren, Zurich, CHE, 8952
Kuros Biosciences Ltd is a Swiss-based biotech company, focused on developing and commercializing biologic bone graft technologies for musculoskeletal applications, particularly in spine, trauma, extremities, and oncology. It has two reportable segments: i) Medical Devices: This segment includes products such as MagnetOs and Attrax, which are biphasic calcium phosphate (BCP) bone grafts that mimic the porous, trabecular structure of cancellous bone. ii) Legacy Portfolio: This segment includes all non-core products (including Checkmate licensing) that are outside the Group's primary therapeutic focus. The majority of the company's revenue is derived from the Medical Devices segment. Geographically, it generates the maximum revenue from the United States of America.
71GF Score

Get the complete analysis for CSBTF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.72
Price
$54.72
GF Value